- Previous Close
64.75 - Open
61.65 - Bid 57.75 x --
- Ask 58.40 x --
- Day's Range
61.65 - 61.65 - 52 Week Range
37.56 - 82.60 - Volume
3 - Avg. Volume
0 - Market Cap (intraday)
1.073B - Beta (5Y Monthly) 1.60
- PE Ratio (TTM)
47.42 - EPS (TTM)
1.30 - Earnings Date May 7, 2025
- Forward Dividend & Yield 0.54 (0.83%)
- Ex-Dividend Date Oct 11, 2024
- 1y Target Est
--
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops as well as develops XcytoMatic 30 cell counter. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.
chemometec.comRecent News: CHY.F
View MorePerformance Overview: CHY.F
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CHY.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CHY.F
View MoreValuation Measures
Market Cap
1.08B
Enterprise Value
1.05B
Trailing P/E
49.71
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.29
Price/Book (mrq)
14.06
Enterprise Value/Revenue
17.03
Enterprise Value/EBITDA
33.02
Financial Highlights
Profitability and Income Statement
Profit Margin
36.79%
Return on Assets (ttm)
19.86%
Return on Equity (ttm)
30.83%
Revenue (ttm)
459.54M
Net Income Avi to Common (ttm)
169.08M
Diluted EPS (ttm)
1.30
Balance Sheet and Cash Flow
Total Cash (mrq)
264.74M
Total Debt/Equity (mrq)
1.30%
Levered Free Cash Flow (ttm)
98.11M